Company Profile

Profile last edited on: 4/26/22      CAGE:       UEI:

Business Identifier: Live attenuated vaccines
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

297 North Bernadardo Avenue
Mountain View, CA 94043
   (650) 919-6500
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

In December 2001 Aviron was acquired by SBIR firm MedImmune - itself having been an SBIR involved firm that later went on to be acquired by AstraZeneca. Aviron was a biopharmaceutical company focused on prevention of disease through devlopment of cost-effective vaccines to justify their use in immunization programs targeting the general population. Aviron's vaccine programs are based on both classical live virus attenuation techniques and the Company's proprietary genetic engineering technologies. The Company's lead product, an influenza vaccine delivered as an intranasal spray (FluMist), has been shown to provide a high protection rate against influenza with minimal adverse effects. Aviron is developing this live vaccine for widespread use in children, healthy adults and high-risk adults. The Company is also developing potential vaccines for Parainfluenza Virus Type 3 (PIV-3), Epstein-Barr Virus (EBV), Congenital Cytomegalovirus (CMV) infection, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus Type 2 (HSV-2).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 2 NIH $1,349,701
Project Title: Rational Design of a Live, attenuated HSV2 Vaccine
2002 2 NIH $849,784
Project Title: Bovine Parainfluenza 3 Virus As A Novel Vaccine Vector
2001 2 NIH $849,337
Project Title: Chimeric Rsv Subgroup A And B Vaccine Candidates
1999 2 NIH $1,052,925
Project Title: Development of Rationally Designed HCMV Vaccine Strains
1999 1 NIH $332,942
Project Title: Mucosal Immunity & Replication Of Human Cytomegalovirus

Key People / Management

  C Boyd Clarke -- President

  Aurelia A Haller

  Hong Jin

  George W Kemble

  Mark Prichard

Company News

There are no news available.